Analysis of prognostic factors for surgery after neo-adjuvant therapy for stage III non-small cell lung cancer

Abstract

In order to explore the possibility to predict the risk factors for postoperative complications and survival time, the clinical data of 152 patients (including 116 males and 36 females) who had undergone neo-adjuvant therapy and surgery for stage IIIA and B non-small cell lung cancer (NSCLC) were retrospectively analyzed. Demographic data, preoperative functional parameters, staging, induction regimen (chemotherapy alone or associated with radiotherapy), associated disorders, and data about operation were collected. Chi-square test and multivariate analysis fitting the unconditional logistic regression model were performed to identify predictors of postoperative complications, while Kaplan-Meier and multivariate Cox proportional hazard model were employed to identify predictors of survival time, respectively. The univariate analysis demonstrated that forced expiratory volume in 1 second predicted percent (FEV1%, P=0.040) and associated disorders (P=0.020) were the predictive factors of complications, but multivariate analysis found no independence factors (P>0.05) of it. Univariate Kaplan-Meier analysis showed that stage (P=0.050) and pneumonectomy (P=0.018) affected the survival time. However, multivariate Cox proportional hazard model analysis demonstrated that only pneumonectomy (P=0.026) was associated with a decreased survival time, but no differences between right and left pneumonectomy were found. The results suggest that the risk factor for postoperative complications is acceptable, and pneumonectomy is associated with increased mortality, which should be performed only in stage III NSCLC patients.

Keywords

non-small cell lung cancer / neo-adjuvant therapy / surgery / prognosis

References

[1] GeorgiosS.. Risks of neoadjuvant chemotherapy and radiation therapy. Thorac Surg Clin, 2008, 18: 71-80

[2] HaruhikoN., NorihitoK., MasahikoT., et al.. Role of preoperative chemotherapy for non-small-cell lung cancer: A meta-analysis. Lung Cancer, 2006, 54: 325-329

[3] Shin-ichiT., HajimeM., TatsuyaO., et al.. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA–IIIB) lung cancer. Eur J Cardiothorac Surg, 2006, 30: 184-189

[4] StamatisG., DjuncD., EberhardtW., et al.. Postoperative morbidity and mortality after induction chemotherapy for locally advanced lung cancer: an analysis of 350 operated patients. Eur J Cardiothorac Surg, 2002, 22: 292-297

[5] PerrotE., GuibertB., MulsantP., et al.. Preoperative chemotherapy does not increase complications after non small cell lung cancer resection. Ann Thorac Surg, 2005, 80: 423-427

[6] MarcR., PatrickB., FrancoiseL. P. B., et al.. Completely re-sected non-small cell lung cancer: Reconsidering prognostic value and significance of n2 metastases. Ann Thorac Surg, 2007, 84: 1818-1824

[7] RobertJ. C., AyeshaS. B.. Surgical techniques and results for partial or circumferential sleeve resection of the pulmonary artery for patients with non-small cell lung cancer. Ann Thorac Surg, 2007, 83: 1971-1977

[8] MicheleD. W., JeroenH., PatrickL., et al.. Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy. Eur J Cardiothorac Surg, 2006, 29: 240-243

[9] GudrunP., GerhardK., RezaM., et al.. Induction chemo-therapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer. Lung Cancer, 2006, 54: 63-67

[10] KarlL. U., GailD., WeiX., et al.. Improved results of induction chemoradiation before surgical intervention for se-lected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg, 2007, 134: 188-193

[11] DepierreA., MilleronB., Morat-SibilotD., et al.. Preoperative chemotherapy followed by surgery compared with primary surgery in respectable stage I (except T1N0), II and IIIA non-small cell lung cancer. J Clin Oncol, 2001, 20: 247-253

[12] BerghmansT., PaesmansM., MeertA. P., et al.. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. Lung Cancer, 2005, 49: 13-23

[13] AlessandroB., FrancescoL., GiuliaV., et al.. Extended pneumonectomy for non-small cell lung cancer: Morbidity, mortality, and long-term results. J Thorac Cardiovasc Surg, 2007, 134: 1266-1272

[14] PatrickB., PascalB., JoaoC., et al.. Sleeve lobectomy ver-sus pneumonectomy: tumor characteristics and com-parative analysis of feasibility and results. Ann Thorac Surg, 2005, 80: 2046-2050

[15] LeoF., SolliP. G., VeronesiG., et al.. Does chemother-apyraise the risk of respiratory complications after pneumonectomy?. J Thorac Cardiovasc Surg, 2006, 132: 519-523

[16] RiceT. W., OkerekeI. C., BlachstoneH. H.. Persistent air leaks following pulmonary resection. Chest Surg Clin N Am, 2002, 12: 529-539

[17] FedericoV., MarcoA., DanieleD., et al.. Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg, 2007, 31: 714-718

[18] MartinJ., GinsbergR. J., AbolhodaA., et al.. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg, 2001, 72: 1149-1154

[19] AdnanA., MuratK., SaadettinC., et al.. Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: A phase II study. Lung Cancer, 2007, 58: 246-252

[20] FabriceB., ChristopheD., Jean-PhilippeT., et al.. Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy. Eur J Cardiothorac Surg, 2005, 28: 629-634

[21] ShiroF., NobuyukiK., YutakaT., et al.. Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer. Eur J Cardiothorac Surg, 2006, 29: 896-901